| Japanese |
|---|
| Title | 過機能性副甲状腺結節の検出における99mTc-MIBIシンチグラフィの臨床的有用性 - 第III相多施設臨床試験報告 - |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 日下部きよ子*1, 大島統男*2, 高見博*3, 村田啓*4, 油野民雄*5, 久保敦司*6 |
|---|
| Authors(kana) | |
|---|
| Organization | *1東京女子医科大学放射線科, *2帝京大学医学部放射線科, *3帝京大学医学部第一外科, *4虎の門病院放射線科 (現 ; 放射線医学総合研究所), *5旭川医科大学放射線科, *6慶應義塾大学医学部放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 35 |
|---|
| Number | 9 |
|---|
| Page | 887-899 |
|---|
| Year/Month | 1998/11 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」過機能性副甲状腺結節の検出における99mTc-MIBIの臨床的有用性を評価するために, 副甲状腺機能亢進症の患者78名を対象に第III相臨床試験を実施した. 1症例において軽度の震えが認められた以外は, 本剤に起因すると思われる身体所見および臨床検査値の異常変動は認められず, 本剤の高い安全性が示唆された. 過機能性副甲状腺結節の有無が確定しなかった8症例を除く70症例において本剤の有効性の解析を行った. 病変の組織型, 病変数, 局在部位にかかわらず高い感度が得られ, 全体の感度は86%であった. 特に単発性, 異所性の病変については高い感度が得られた. 重量が判明した53腺中200mg以上の36腺の感度は94%であり, 200mg程度の病変は十分に検出可能であると思われた. 以上より, 本剤は過機能性副甲状腺結節の検出において安全で有用な薬剤であると考えられた. 「I. はじめに」副甲状腺は通常4腺からなり, 2個は甲状腺側葉の各上方部分, 2個は下方部分後方に位置する. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-MIBI, Hyperparathyroidism, Parathyroid adenoma, Parathyroid hyperplasia, Parathyroid carcinoma. |
|---|
| English |
|---|
| Title | Evaluation of Clinical Utility of 99mTc-MIBI Scintigraphy in the Localization of Hyperfunctioning Parathyroid Lesions in Patients with Hyperparathyroidism - A Report of Multicenter Phase III Clinical Trials - |
|---|
| Subtitle | |
|---|
| Authors | Kiyoko KUSAKABE*1, Motoo OSHIMA*2, Hiroshi TAKAMI*3, Hajime MURATA*4, Tamio ABURANO*5, Atsushi KUBO*6 |
|---|
| Authors(kana) | |
|---|
| Organization | *1Department of Radiology, Tokyo Women's Medical College, *2Department of Radiology, Teikyo University School of Medicine, *3First Department of Surgery, Teikyo University School of Medicine, *4Division of Nuclear Medicine, Toranomon Hospital, *5Department of Radiology, Asahikawa Medical College, *6Department of Radiology, School of Medicine, Keio University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 35 |
|---|
| Number | 9 |
|---|
| Page | 887-899 |
|---|
| Year/Month | 1998/11 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Phase III clinical study in 78 patients with hyperparathyroidism was performed to determine clinical utility of 99mTc-MIBI in the localization of hyperfunctioning parathyroid lesions. Except slight tremor in one patient, no adverse events were reported. No abnormal changes in clinical laboratories or vital signs were noted. The clinical utility of the agent was evaluated in 70 patients. Out of 108 hyperfunctioning glands, 93 (86%) were detected with 99mTc-MIBI regardless of their histology, numbers, or location. Specifically, single or ectopic lesions were detected with high sensitivity (97% and 100%, respectively). Sensitivity in 53 glands with weight data was 79%, while 94% in 36 glands above 200mg, which is extremely high compared to the 201Tl-99mTc subtraction method. Specificity in a group of PHP patients with single adenoma who underwent surgery was 100% (63/63), though in case of coexistent thyroid disease obviously interfered parathyroid images. Our study indicates that 99mTc-MIBI is a safe and excellent agent for the localization of hyperfunctioning parathyroid tissues. Especially, the fact that 99mTc-MIBI detected ectopic glands with high specificity is a great advantage over the ultrasound or 201Tl-99mTc subtraction method. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-MIBI, Hyperparathyroidism, Parathyroid adenoma, Parathyroid hyperplasia, Parathyroid carcinoma. |
|---|